Trending...
- Eddy Corp and SMAART POWER LLC Announce Strategic Teaming Agreement to Accelerate Microgrid and Distributed Energy Deployments - 228
- California: Governor Newsom expands film and TV tax credits with new legislation, creates tax credit to support post-production jobs - 172
- California: Governor Newsom issues legislative update 9.18.26 - 154
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Homology Medicines, Inc.. ("Homology" or "the Company") (NASDAQ: FIXX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Homology is the subject of a report published by Mariner Research on July 21, 2020. The report questions the efficacy of the Company's lead product candidate, HMI-102. The report alleges that the company concealed efficacy information and predicted that the drug would not continue to commercialization. Based on this report, shares of Homology dropped by more than 10% on July 24, 2020.
More on The Californer
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Homology is the subject of a report published by Mariner Research on July 21, 2020. The report questions the efficacy of the Company's lead product candidate, HMI-102. The report alleges that the company concealed efficacy information and predicted that the drug would not continue to commercialization. Based on this report, shares of Homology dropped by more than 10% on July 24, 2020.
More on The Californer
- California: Governor Newsom applauds federal film and TV tax credit bill, answering his call to keep production in America
- Noted Political Commentator a Major Influencer with multiple Millions of Viewers
- Marissa Goodbody's The Sloth, the Shrew, & the Cockatoo Takes Young Readers on a Rhyming Adventure
- NEW: Report shows major progress in California on preparing for wildfire, avoiding millions of tons of carbon pollution and toxic smoke
- Governor Newsom on the California Supreme Court ruling Sheriff Bianco illegally seized ballots
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Filed Under: Business
0 Comments
Latest on The Californer
- Sonoma County's Largest Pop-up Used Book Sale Benefits Five Sonoma County Libraries
- Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
- PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
- Save 15 Percent Off Florida Keys Accommodations with KeysCaribbean's Advance Purchase Rate Discount
- Woodside Rehab & Nursing Enters a New Era of Clinical Excellence and Growth
- Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
- Atticus Pharma Awarded $2 Million NIH Phase II SBIR Grant to Advance Cutaneous Lupus Drug Candidate
- Fall Jewellery Trends 2026: 3 Bracelets That Instantly Elevate Your Autumn Style
- iPOP! Alum Lucas Till Stars Alongside Zach Braff in Upcoming Film Clean Hands
- Lil Sicc Ent. Announces new chapter w/ Dectv.tv
- Glympse Job Finder Launches, Bringing a More Personal Approach to Job Matching
- Pasadena Advisory Firm Launches Free 1031 Exchange Guide for Real Estate Owners
- California: Governor Newsom calls out Trump's climate failure at the United Nations
- Fibromyalgia, It's Ayurvedic Prevention, Treatment and Cure, Dr. Abhay Kumar Pati, USA
- Home Assault Incident Involving Founder Oliver B. Mitchell III
- Last-Minute Travel Deals for Solo Senior Travelers Include No Single Supplement Opportunities
- Night Guardians Partners with Raven Donuts to Support Animal Rescue and Community Awareness
- Port St. Lucie REALTOR® Irene Pernice Earns SFR® Certification
- AMR and UAS Take the Stage at WorldSkills Shanghai 2026
- City of Long Beach Opens Applications for Third Cohort of Long Beach Fire Corps Program